Elsevier

The Lancet

Volume 351, Issue 9117, 6 June 1998, Pages 1722-1725
The Lancet

Department of Medical History
Powerful placebo: the dark side of the randomised controlled trial

https://doi.org/10.1016/S0140-6736(97)10111-8Get rights and content

Section snippets

Pre-RCT placebo

When pre-World War II paternalistic ethics prevailed, informed consent was not a standard of care.1 Physicians were generally comfortable with benevolent deception and a “polychromatic assortment of sugar pills” was routinely swallowed by patients.2, 3 In 1903, Richard Cabot (1868–1939), the eminent professor at Harvard Medical School, described the placebo's persuasiveness. He was “brought up, as I suppose every physician is, to use placebo, bread pills, water subcutaneously, and other

RCT placebo effect

In 1955, the modern biomedical concept of the placebo makes its first definitive appearance with the publication of Henry Beecher's (1904–1976), “The Powerful Placebo” in the Journal of the American Medical Association (JAMA)11 Beecher, a distinguished medical researcher at Harvard Medical School, summarised and mathematically presented a perspective that had been developing in a few elite biomedical research centres since 1946.12 Beecher used a proto-meta-analytic method to aggregate the

RCT and creation of the modern placebo

World War II has been called the great divide in medical research and certainly, for the placebo, this is true. In fact, the “powerful placebo” was born in the vortex of one of medicine's most momentous transitions. Before World War II the evaluation of new therapeutics was made by recognised leaders of the medical profession whose judgments were based on clinical impressions, and on rare occasions, poorly controlled evidence.21 In an effort to impose an objective and scientific discipline onto

Powerful placebo and acceptance of RCT

Medical proponents of the RCT were under pressure to convince their colleagues of the RCT's value.23 Few physicians wanted randomly to assign treatment to patients, forgo the individualisation of therapy, and withhold promising new therapies. Austin Bradford Hill (1897–1991), the designer of the first randomised trial, many years later confessed that he “deliberately left out the words ‘randomisation’ and ‘random sampling numbers’ at the time because… I might have scared them [collaborating

RCT and placebo: the light and dark of a partnership

Elite medical reformers created a symbiosis between the RCT and the powerful placebo effect. A new gold standard was constructed to fit the new technical procedures. Until the RCT, medical therapy became legitimate because of beneficial outcomes; after the RCT, a medical intervention was only scientifically acceptable if it was superior to placebo.34 No longer was it sufficient for a therapy to work: it had to be better than placebo. For the first time in history (outside of religious healing

RCT and powerful placebo at 50 years

The powerful placebo is a modern entity constructed in the shadow of the RCT. In the current RCT era, a legitimate therapy must demonstrate an effect greater than a decoy disguised as a real intervention. Yet, under the rhetorical label of powerful placebo lies many rich contributions to health care. These include: nature taking its course; regression to the mean; routine medical and nursing care; regimens such as rest, diet, exercise, and relaxation; easing of anxiety by diagnosis and

First page preview

First page preview
Click to open first page preview

References (42)

  • DH Tuke

    Illustrations of the influence of the mind upon the body in health and disease designed to elucidate the action of the imagination

    (1884)
  • DE Shideman et al.

    Comments on treatment

    Wisconsin Med J

    (1958)
  • OHP Pepper

    A note on the placebo

    Am J Pharm

    (1945)
  • Anon

    The humble humbug

    Lancet

    (1954)
  • HK Beecher

    The powerful placebo

    J Am Med Assoc

    (1955)
  • The use of placebos in therapy

    N Y J Med

    (1946)
  • B Spilker

    Guide to clinical trials

    (1991)
  • RP Liberman

    The elusive placebo reactor

    Neuropsychopharm

    (1967)
  • CRB Joyce

    Placebos and other comparative treatments

    Br J Clin Pharmacol

    (1982)
  • DE Moerman

    General medical effectiveness and human biology: placebo effects in the treatment of ulcer disease

    Med Anthropol

    (1983)
  • HK Beecher et al.

    The effectiveness of placebo “reactors” and “non-reactors”

    J Pharmacol Exp Ther

    (1953)
  • Cited by (308)

    • Should we consider the indication of placebo in clinical practice?

      2023, Revista Espanola de Anestesiologia y Reanimacion
    View all citing articles on Scopus
    View full text